NDAORALCAPSULE, DELAYED RELEASE
Approved
Dec 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
TRILIPIX (fenofibric acid) by AbbVie is delayed-release capsules is fenofibric acid. First approved in 2008.
Drug data last refreshed 13h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRILIPIX (fenofibric acid) is an oral delayed-release capsule containing a peroxisome proliferator receptor alpha (PPARα) agonist that activates lipoprotein lipase and reduces triglyceride-rich particles from plasma. It is indicated for patients with elevated triglycerides and is used as an adjunctive therapy in lipid management. The drug works by increasing lipolysis and eliminating apoprotein C-III, thereby improving the lipid profile in dyslipidemic patients.
$0.307MPart D
LOE ApproachingProduct is approaching loss of exclusivity with modest Part D utilization (523 claims in 2023), signaling a contracting commercial opportunity and likely reduced team headcount and investment.
Mechanism of Action
delayed-release capsules is fenofibric acid. The pharmacological effects of fenofibric acid in both animals and humans have been studied through oral administration of fenofibrate. The lipid-modifying effects of fenofibric acid seen in clinical practice have been explained in vivo in transgenic…
Pharmacologic Class:
Peroxisome Proliferator Receptor alpha Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Study of Trilipix Effects on Lipids and Arteries
Started Nov 2009
24 enrolled
Dyslipidemia
Comparison of Fenofibric Acid Bioavailability From ABT-335 Capsules
Started Feb 2009
32 enrolled
Healthy
Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium
Started Dec 2008
90 enrolled
Healthy
Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From 5/45 mg Strength of ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) 45 mg and Rosuvastatin Calcium 5 mg
Started Nov 2008
90 enrolled
Healthy
Worked on TRILIPIX at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.